Evidence map›Paper›PMID 39594145›Full record

ArticleDiagnostics (Basel, Switzerland)2024

Demonstration of T-Cell Monotypia Using Anti-TCRbeta1/2 (

Elizabeth J Soilleux, Daniel T Rodgers, Jinlong J Situ, Shelley C Evans, Venkata N Konda, Han-Chieh Yang, Jianxiong Pang, Isabella Gilbey Smith, Pete Rajesh, Maryam Salimi and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Special Issue "Flow Cytometry: Applications and Challenges".International journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Elizabeth J SoilleuxDepartment of Pathology, University of Cambridge, Cambridge CB2 0SP, UK.ORCID 0000-0002-4032-7249
Daniel T RodgersHuman Research Tissue Bank, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Jinlong J SituDepartment of Pathology, University of Cambridge, Cambridge CB2 0SP, UK.
Shelley C EvansDepartment of Pathology, University of Cambridge, Cambridge CB2 0SP, UK.ORCID 0000-0003-3242-6017
Venkata N KondaDepartment of Pathology, University of Cambridge, Cambridge CB2 0SP, UK.
Han-Chieh YangDepartment of Pathology, University of Cambridge, Cambridge CB2 0SP, UK.
Jianxiong PangDepartment of Pathology, University of Cambridge, Cambridge CB2 0SP, UK.ORCID 0009-0009-3230-3384
Isabella Gilbey SmithDepartment of Pathology, University of Cambridge, Cambridge CB2 0SP, UK.
Pete RajeshDepartment of Pathology, University of Cambridge, Cambridge CB2 0SP, UK.
Maryam SalimiMRC Translational Immune Discovery Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK.
Soo Weei NgMRC Translational Immune Discovery Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK.ORCID 0000-0002-9867-6353
Julia JonesCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.ORCID 0000-0001-9819-8091
Jodi L MillerCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge CB2 0RE, UK.ORCID 0000-0001-6870-204X
Rachel EtheringtonMRC Translational Immune Discovery Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK.ORCID 0000-0002-4348-4565
Margaret Ashton-KeyDepartment of Cellular Pathology, University Hospital Southampton, Southampton SO16 6YD, UK.
Graham OggMRC Translational Immune Discovery Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK.

Funding

Cambridge Biomedical Research Centre 0000Medical Research Council UK 0000NIHR Cambridge Biomedical Research Centre NIHR203312Oxford University Challenge Seed Fund 0000Oxford University Innovation Medical and Life Sciences Translational Fund, 0000Pathological Society of Great Britain and Ireland 0000University of Cambridge Career Support Fund Returning Carer's Scheme 0000
6 · The paper itself

Abstract

BACKGROUND/

objectivesT-cell lymphomas are often histologically indistinguishable from benign T-cell infiltrates, and diagnosis typically relies on slow, complex, and expensive multiplexed PCR reactions, requiring significant training and experience to interpret them. We aimed to raise highly specific antibodies against the two alternatively used and very similar T-cell receptor beta constant regions, TCRbeta1 and TCRbeta2, encoded by the

methodsRecombinant rabbit antibodies were validated using Western blotting and FFPE immunostaining of T-cell leukemia lines. The immunostaining of FFPE tissue containing benign and lymphomatous T-cell populations was undertaken, with corroboration by BaseScope

resultsOur TCRbeta1/TCRbeta2 antibody pair gave highly specific FFPE tissue staining. All benign samples analyzed (immunohistochemically, by BaseScope

conclusionsAnalyzing T-cell monotypia immunohistochemically, analogous to B-cell monotypia (kappa: lambda ratio for B-cell and plasma cell neoplasms), could make the diagnosis of T-cell lymphomas cheaper, quicker, and more accurate. Larger studies are needed to validate our antibodies for clinical use.

Indexed as

clonalitydiagnostic testformalin-fixed paraffin-embedded tissueimmunohistochemistrylymphomamonotypia

Identifiers

PMID39594145
PMCPMC11593183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.